Leadgene Biomedical Expands in Northern Taiwan with New Innovation & Research Center and CLD Center

"In the next five years, we aim to become the leading force in Asia in the field of nanobody (VHH Service) research!" Leadgene Biomedical, which has its roots in Tainan, has officially expanded to northern Taiwan with two new branches after more than a year of planning.

Alongside the establishment of a Cell Line Development Center (CLD Center) in Taipei’s Zhongshan District, an Innovation & Research Center has been launched in Xike. A grand opening tea reception was held on August 1st, welcoming partners and experts to join in the celebration.

Dr. Chasel Yung-Chun Chuang, Chairman of Leadgene Biomedical, noted that the initial concept was conceived as early as 2016, though it required additional time to bring to fruition. Moving forward, the company will remain true to its core philosophy, "Lead the way, Blaze the way," by continuing to pioneer in relevant fields.

The expertise accumulated over 12 years is now being brought to northern Taiwan to provide services to more companies. "Especially in the innovative research and development of nanobodies (VHH Service), we have collaborated on over 680 projects this year alone, with more than 30% making significant progress. We aim to become the leader in Asia within five years!" Dr. Chuang emphasized.

The company is dedicated to the development of biological raw materials, beginning with localization and followed by stable mass production. Additionally, Leadgene continues to develop immunoassay platforms, enhance its capabilities, expand into in vitro diagnostic reagents (IVD), and offer contract development and manufacturing services (CDMO), all while maintaining certified quality standards.

The opening reception was attended by numerous distinguished guests and partners. In his speech, Professor Paik-Seong Lim, Director of Nephrology at Tungs’ Taichung MetroHarbor Hospital, expressed his admiration for Leadgene Biomedical’s "decade-long perseverance," praising the team's relentless spirit, wisdom, and grand vision. Professor Te-Chao Fang, Supervisor of the Taiwan Society of Nephrology and Vice Director of the Department of Internal Medicine at Taipei Medical University Hospital, highlighted the challenges involved in developing the "Leadgene" Indoxyl Sulfate (IS) ELISA Kit, emphasizing the importance of its widespread adoption to benefit kidney disease patients by providing them with better care. "If we compare this to competing in the World Cup, this is truly a source of pride for Taiwan!"

Leadgene Biomedical currently produces over 500 products and holds more than eight patents. The company excels in innovative technology development and the production of high-quality proteins and antibody reagents. Looking ahead, Leadgene plans to offer customized, one-stop services, expanding into the field of cell line development. Utilizing new automated equipment like "C. STATION," which integrates liquid handling modules, data analysis, incubators, and other robotic arm-operated equipment, Leadgene aims to reduce biologic production costs to just one-fifth of that in traditional laboratories. Charles Tsai, CEO of Cytena Bioprocess Solution, also expressed his anticipation that the cell line development platform in northern Taiwan, with the continuous introduction of related equipment, will create a significant breakthrough for Taiwan!